Close Menu

Breaking News

The firm saw steady growth in its research reagents and screening businesses, and a 155 percent revenue increase in its bioproduction unit.

Last week, GenomeWeb's readers were most interested in Illumina's suit challenging a patent awarded to Columbia University for NGS technology.

Interpace Diagnostics subsidiary Interpace BioPharma will perform services worldwide, while Genecast will offer the services in China.

The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.

As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.

The European companies aim to link individuals who have used direct-to-consumer genetic tests with clinical trials and other research programs.

Get the latest news from Illumina, TRC, Diagnomics, Danaher, BioDiscovery and Abbot for the week of 9/13/19

Divesting the cord blood business will allow Natera to focus on its genetic testing business in reproductive health, oncology, and organ transplantation.

The team will use a combination of genomics, pathology, and computer modeling to identify potential new therapeutic targets of the disease.

The firm said that on Oct. 13 it will redeem all of its outstanding 5 percent unsecured notes due in 2021.

The Radiance platform uses laser force cytology technology to measure optical and fluidic forces within a microfluidic channel for cellular analysis.

Thermo Fisher Scientific said today that it plans to redeem two classes of senior notes later this month, with a total aggregate principal amount of $1.1 billion.

The Pleasanton, California-based single-cell sequencing firm said that net proceeds of the IPO will be approximately $357.5 million.

he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.

The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.

Machine learning and DNA methylation analyses helped distinguish between primary lung tumors and lung tumors stemming from head and neck cancer metastasis.

Researchers identified Streptococcus pyogenes isolates from a lineage dubbed M1UK that are predicted to produce higher-than-usual levels of a scarlet fever-associated toxin.

The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.

The UK-based sequencing technology firm continues to seek invalidation of PacBio's patents, despite unsuccessful earlier efforts.

The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform. 

Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.

About $770 million in net proceeds will go toward the repayment of outstanding debt under its senior unsecured revolving credit facility.

The firms have developed a cannabis sequencing panel, called myBaits MGC Cannabis Panel, which they will be offering  for sequencing service work.

Pages

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.